> No interaction studies have been performed.  Sirolimus is extensively metabolis ed by the CYP3A4 isoenzyme, and it is a substrate for the multidrug efflux pump P -glycoprotein (P -gp). In addition, sirolimus has been shown to inhibit human liver microsomal cytochrome P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5 in vitro . In the light of the low systemic exposure after topical administration it is not expected that clinical relevant interactions will occur, but HYFTOR  should be used with caution in patients  taking respective concomitant medicinal products . Potential adverse reactions should be monitored and in case observed , treatment should be interrupted. 
